- Report
- June 2026
- 180 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,519GBP
- Report
- April 2026
- 149 Pages
Global
From €3635EUR$3,999USD£3,135GBP
- Report
- May 2026
- 134 Pages
Global
From €4408EUR$4,850USD£3,802GBP
- Report
- March 2025
- 200 Pages
India
From €2263EUR$2,490USD£1,952GBP
- Report
- September 2025
- 70 Pages
India
From €3181EUR$3,500USD£2,743GBP
- Report
- September 2025
- 88 Pages
India
From €3181EUR$3,500USD£2,743GBP
- Report
- October 2024
- 270 Pages
China
From €3636EUR$4,000USD£3,135GBP
- Report
- July 2025
- 88 Pages
Global
From €3500EUR$4,125USD£3,124GBP
- Report
- October 2024
- 135 Pages
China
From €1636EUR$1,800USD£1,411GBP
Cefixime is an antibiotic used to treat a variety of bacterial infections. It belongs to the third-generation cephalosporin class of antibiotics, which are used to treat infections caused by Gram-negative bacteria. Cefixime is used to treat a wide range of infections, including ear infections, urinary tract infections, and respiratory tract infections. It is also used to treat gonorrhea, a sexually transmitted infection. Cefixime is available in both oral and injectable forms.
Cefixime is a widely used antibiotic in the treatment of bacterial infections. It is generally well tolerated and has a low risk of side effects. It is also cost-effective, making it a popular choice for treating bacterial infections.
Some companies in the Cefixime market include GlaxoSmithKline, Pfizer, Merck, and Sanofi. Show Less Read more
